Top Gainers With Unusual Volume (MRX, HEK, PPHM, CHTP)

Los Angelas, CA -- (SBWIRE) -- 09/05/2012 -- Medicis Pharmaceu (NYSE:MRX) is very active today and traded between $43.42 - 43.70 with total traded volume of 31508642 shares. At a current price of 43.65, MRX is +12.09 - +38.31% from the previous close of $31.56. Moreover, At Current Market Price, MRX is in distance of +30.90% from its 50-day Moving Average price of $33.3457 and +23.06% from its 200-day Moving Average price of $35.4709. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Analysts expect that Medicis Pharmaceutic will post $2.46 EPS for the current fiscal year. When the news was published RBC Capital raised their price target on shares of Medicis Pharmaceutic from $37.00 to $44.00 in a research note to investors on Tuesday.

FORE MORE DETAILS ABOUT MRX JUST CLICK HERE:

Heckmann Corporat (NYSE:HEK) reported EPS of -0.133. For the Current Fiscal year, the company is expected to report EPS of 0.05. For the Next Quarter and Next Year, the company is expected to report EPS of 0.01 and 0.07 respectively. At Current Market Price, HEK is in distance of +24.66% from its 50-day Moving Average price of $2.976 and +0.71% from its 200-day Moving Average price of $3.6837. Heckmann Chairman & CEO Richard Heckmann discusses his company's announcement that it will buy Badlands Energy LLC. This deal makes Heckmann the largest pure play on handling fracking fluids, and it also gives them exposure to the Bakken shale in North Dakota, perhaps the largest domestic oil find since Prudhoe Bay in the sixties.

GET THE NEXT TREND ABOUT THIS STOCK VISIT NOW:

Shares of Peregrine Pharmac (NCM:PPHM) are trading at $2.93 and is +39.35% from its 50-day Moving Average price of $2.1026 and +201.04% from its 200-day Moving Average price of $0.9733. The average trading volume is 2699420 shares and its market capitalization is $305.2M.The company also announced that it will report financial results for the first quarter of the fiscal year 2013 on September 10, 2012 before market and will host a conference call and webcast at 8:00 AM PDT (11:00 AM EDT). Peregrine's senior management will discuss financial results for the first quarter of fiscal year ended July 30, 2012 and will review progress of its clinical development programs, including an overview of the bavituximab data that will be presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology on September 7, 2012.

To know more the prospective result click here:

Shares of Chelsea Therapeut (NCM:CHTP) are trading at $1.25 and is +18.53% from its 50-day Moving Average price of $1.0546 and -34.40% from its 200-day Moving Average price of $1.9056. The average trading volume is 1194180 shares and its market capitalization is $83.8M. Chelsea Therapeutics International, Ltd. (CHTP) is scheduled to present at the 14th Annual Rodman & Renshaw Global Healthcare Investment Conference at 3:40 PM ET on Monday, September 10, 2012 at the Waldorf Astoria in New York City.

To know more the prospective result click here:

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com